Answers are grounded in this paper and cite their sources.
• Hypoxanthine and potassium oxonate intraperitoneally for 7 days, induced hyperuricemia in rats. • Methanolic extract of Aquilaria malaccensis (AMME) phytoconstituents exhibited strong binding affinity with the xanthine oxidase enzyme (PDB ID: 1FIQ ). • AMME demonstrated in vitro membrane-stabilizing activity, indicating potential anti-inflammatory effects. • AMME significantly reduced hypoxanthine and potassium oxonate-induced elevation of serum uric acid levels in rats. • AMME treatment restored altered renal tissue architecture and improved joint morphology in hyperuricemic rats. Hyperuricemia, characterized by elevated serum uric acid (UA), is a major risk factor for gout, renal injury, and osteoarthritic complications. Current urate-lowering agents can cause adverse effects. Aquilaria malaccensis (沉香, Chénxiāng, AM), traditionally used in Traditional Chinese Medicine (TCM) to regulate Qi, relieve pain, and support renal function, contains flavonoid-rich constituents that may offer metabolic and anti-inflammatory benefits. This study investigates the anti-hyperuricemic potential of A. malaccensis methanolic extract (AMME) through phytochemical, in vitro, in vivo , and in silico approaches. Methanolic leaf extract of authenticated AM was subjected to phytochemical screening, TLC, UV–Vis, and FT-IR characterization. Molecular docking was performed with xanthine oxidase (XO, PDB: 1FIQ). Hyperuricemia was induced in rats using potassium oxonate and hypoxanthine, followed by treatment with AMME. Serum uric acid (UA) and C-reactive protein (CRP) levels were quantified, while renal histopathological analysis, knee joint radiography, and an in vitro membrane-stabilization assay were performed to evaluate protective and anti-inflammatory effects. Flavonoids such as acacetin, luteolin derivatives, and 5-hydroxy-7,4′-dimethoxyflavone were identified (TLC Rf = 0.84; UV–Vis λ_max = 210, 258 nm). Docking showed favourable interactions of these compounds with XO. AMME exhibited notable membrane stabilization (85.8% inhibition at 800 µg/mL; IC₅₀ = 143.56 µg/mL). In vivo, AMME (500–1000 mg/kg) significantly reduced serum UA and CRP levels and ameliorated renal and articular alterations. Flavonoid-rich AMME exhibited anti-hyperuricemic, anti-inflammatory, and renoprotective activities, supporting the traditional use of AM. Further studies on active-compound isolation, mechanistic validation, and pharmacokinetics are warranted.
No takes yet. Share an insight, caveat, or question.
Jagtap et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: